Translational, Epidemiological and Clinical Oncological Research Group (GIOTEC)

ONCOLOGY
TARGETS

The IISPV’s Cancer Research Group aims to research the three main levels of oncological knowledge: population level, individual level, and molecular level.

 

  • · At the population level, epidemiological data are studied from the Tarragona Cancer Registry and the results of population screening programs are reported.

 

  • · From the individual point of view (patient-level), clinical trials are performed with new drugs or new combinations of the same in most tumor locations.

 

  • · At the basic or molecular level, the Unit focuses on mutations in hereditary cancer, somatic tumor mutations, the relationship between lipids and cancer, and metabolomic studies in different tumors from both a diagnostic and prognostic point of view.
RESPONSIBLE
  • Dr. Joan Lluís Borràs Balada

  • Dr. Josep Gumà Padró

  • Research lines
  • Group members
  • Structures and thesis
  • Projects
  • TRANSFER
  • Networks
  • Publications
  • Contact

Clinical Research
Head: Dr. Joan Borràs Balada
Study’s coordinator: Berta Caballé Gutiérrez

Clinical trials in phases II and III, and Real-World Studies of the main tumor locations.
Basket Trial-type clinical trials for tumors with certain genetic mutations.
Studies of prognostic and predictive response factors.

 

Epidemiological research
Head: Dr. Jaume Galceran

In the field of epidemiological research, it focuses on population-based studies related to the Tarragona Cancer Registry.
In the field of prevention research focuses on studies related to cancer screening.

 

Basic and traslational research (Head Dr. Josep Gumà)
The research group focuses on the genomic and metabolic study of cancer, including the identification of hereditary mutations and the investigation of treatment response biomarkers. They also explore the role of the intestinal microbiota in immunotherapy response and its use in early cancer diagnosis.

  1. Hereditary breast and ovarian cancer (HBOC)

Head: Dra. Marta Rodríguez

  1. Advanced metabolomics and cancer

Head: Dra. Raquel Cumeras

  1. Microbiome and cancer

Head: Dr. Josep Gumà

  1. Precision oncology

Head: Dr. Francesc Riu

 

Research in psychooncology
Head: Dra. Agustina Sirgo

Study the impact of oncological disease. At the social level, the study of the benefits of the self-help group of women with breast cancer.

    Structures

  • Clinical Oncology Research Unit (URCO): structure where the Clinical Trials of the Institute of Oncology of Southern Catalonia are carried out. It has study, bioinformatics and administrative coordinators.

    The coordinator of the group is Dr. Joan Borràs Balada.

  • Oncology Molecular Pathology Unit (UPMO): structure created from the collaboration of the Oncology and Pathology services of the Sant Joan de Reus University Hospital. Doctors from the Medical Oncology Service, biologists from the Hereditary Cancer Unit and doctors and biotechnologists from the Pathological Anatomy Service are participating.

    The coordinators of this structure are Dr. Josep Gumà Padró and Dr. Francesc Riu Ferrando.

  • Epidemiology and Cancer Prevention Service (SEPC): service of the Sant Joan de Reus University Hospital dedicated to epidemiological research and population registration of cancer.

    The coordinator of the group is Dr. Jaume Galceran Padrós.

     

     

     

    Thesis

  • Impact of fatty acid metabolism in breast cancer peritumoral tissue. Clinical and pathogenic aspects.
    Author: Jose Adriá Cebrián
    Directors: Dr. Josep Gumà Padró, Dr. Sandra Guaita Esteruelas
    Doctoral Program at Universitat Rovira i Virgili: Biomedicine
    Defense Date: 2022, May 6.

    Grade: Excellent Cum Laude (maximum grade in Spanish University system)
    Current job: Medial writer at Novarti

  • Axillary salvage after neoadjuvant chemotherapy in cN1 breast cancer patients: combined sentinel node-axillary ROLL technique
    Author: Jordi Fuentes Manuel
    Director: Josep Gumà Padró
    Doctoral Program at Universitat Rovira i Virgili: Biomedicine
    Defense Date: 2022, July 8
    Grade: Excel·lent Cum Laude (maximum grade in Spanish University system)

    Current job: Head of Nuclear medicine department of Hospital Universitari Sant Joan de Reus

  • Application of omic techniques to improve the diagnosis of hereditary breast and ovarian cancer syndrome
    Author: Marta Rodríguez Balada.
    Directors: Lourdes Martorell, Dr. Josep Gumà Padró
    Doctoral Program at Universitat Rovira i Virgili: Biomedicine
    Defense Date: 2020, November 13
    Grade: Excel·lent Cum Laude (maximum grade in Spanish University system)

    Current job: Head of a GIOTEC’s research line. Head of the genetic counseling unit of Institut d’Oncologia de la Catalunya Sud

  • Usefulness of cognition-guided biopsies by MRI to improve the detection of prostate cancer
    Author: José García Bennett
    Directors: Joan Carles Vilanova Busquets, Dr. Josep Gumà Padró
    Doctoral Program at Universitat Rovira i Virgili: Biomedicine
    Defense Date: 2018, March 12
    Excel·lent Cum Laude (maximum grade in Spanish University system)

    Current job: Radiologist at Hospital Univ. de Bellvitge.

  • Epidemiología de las neoplasias malignas de ovario en Tarragona, 1980-2005.
    Author: Antonio Llueca Abella.
    Directors: Joan Lluís Borràs Balada, Dr. Josep Gumà Padró.
    Doctoral Program at Universitat Rovira i Virgili: Biomedicine
    Defense Date: 2012
    Apt Cum Laude

  • Epidemiologia de les neoplàsies limfoides a les comarques de Tarragona, 1980-2004
    Author: Josep Gumà Padró
    Director: Joan Lluís Borràs Balada
    Doctoral Program at Universitat Rovira i Virgili: Biomedicine
    Defense Date: 2010

    Research projects

  • COLOOPT Dx Colorectal diagnostic test for an optimal patient screening
    Principal Investigator: Raquel Cumeras
    Reference: DTS21/00113
    Funding body: ISCIII, Instituto de Salud Carlos III
    Budget: 103.400 €
    Period: 01/01/2022-31/12/2023

  • RRHmet Predictive plasmatic metabolomic profile of germline mutations involved in DNA Homologous Recombination Repair
    Principal Investigator: Josep Gumà. Co-PI: Raquel Cumeras.
    Reference: PR-010/2022
    Funding body.: Lliga contra el càncer de les Comarques de Tarragona i Terres de l’Ebre
    Budget:500 €
    Period: 15/12/2022-14/12/2023

  • INVESTIGO Postdoc contract
    Principal Investigator: Raquel Cumeras.
    Reference: PR-010/2022
    Funding body.: AGAUR, Agència de Gestió d’Ajuts Universitaris i de Recerca
    Budget:218 €
    Period: 23/12/2022-21/12/2024

  • ORION Urinary ionomics in the progression of colorectal cancer
    Principal Investigator: Raquel Cumeras, co-PI: Maria Llambrich
    Reference: 2021 LLAV 00050
    Funding body: AGAUR, Agència de Gestió d’Ajuts Universitaris i de Recerca
    Budget: 20.000 €
    Period: 12/10/2022-11/07/2023

  • COLOVOC Reliable and specific urinary biomarkers for colorectal cancer
    Principal Investigator: Raquel Cumeras (IISPV)
    Reference: 798038
    Funding body: EU Marie Skłodowska-Curie Actions call Individual Fellowships as Outgoing
    Participants: UC Davis (US), IISPV (ES), and Biosfer Teslab SL (ES)
    Budget: 257.191 €.
    Period: 01/07/2019 – 29/04/2023

  • MetBioCan Metabolomics from biofluids in cancer
    Principal Investigator: Josep Gumà. Co-PI: Raquel Cumeras.
    Reference: PR-003/2022
    Funding body.: Lliga contra el càncer de les Comarques de Tarragona i Terres de l’Ebre
    Budget:830 €
    Period: 15/07/2022-14/11/2022

  • LIFE FLUIDS Which fluids do we have in the human body?
    Principal Investigator: Raquel Cumeras
    Reference: 415
    Funding body: Fundació Catalana per a la Recerca i la Innovació
    Budget: 3.805 €
    Period: 01/01/2022-31/12/2022

  • Suport a Grups de Recerca (SGR) URV – IISPV finançament – Grup de Recerca consolidat.
    Principal Investigator: Josep Gumà
    Reference: 2021 SGR 00818
    Funding body: AGAUR, Agència de Gestió d’Ajuts Universitaris i de Recerca
    Period: 31/12/2021-30/12/2024

  • Suport a Grups de Recerca (SGR) URV – IISPV finançament – Grup de Recerca consolidat.
    Principal Investigator: Joan Lluís Borràs Balada
    Reference: 2017 SGR 00628
    Funding body: AGAUR, Agència de Gestió d’Ajuts Universitaris i de Recerca
    Period: 2017 – 2021

     

     

     

    Participation in research projects

  • TargetML Developing a Signal Processing Pipeline for Targeted Quantitative Metabolomics and Machine Learning-Based Discovery of Volatile Biomarkers: Application to Cancer Screening
    Principal Investigator: Jesús Brezmes Llecha
    Reference: PID2021-126543OB-C22
    Participating GIOTEC members: Inés Cabezas, Cristina Miracle, Josep Gumà, Raquel Cumeras
    Funding entity: MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union NextGenerationEU/PRTR”
    Budget: 323 €
    Period: 01/09/2022 – 31/08/2025

  • OMIVECA Development and validation of a metabolomic score for pro-vegetarian diets and its relationship with metabolic pathways implicated in cancer
    Principal Investigator: Esther Molina (UGR), Dr. Adela Castelló (ISCIII, CNE).
    Reference: TED2021-130081B-C21
    Participating GIOTEC members: Raquel Cumeras
    Funding entity: CIBER, Centro de Investigación Biomédica en Red
    Budget: 49.600 €
    Period: 01/01/2023 – 31/12/2024

  • CAROL A comprehensive Computer-Aided diagnosis (CAD) system based on RadiOlogic digitaL image biomarkers for prognosis of breast cancer relapse
    Principal Investigator: Domènec Savi Puig Valls (URV)
    Reference: TED2021-130081B-C21
    Participating GIOTEC members: Josep Gumà Padró, Kepa Amillano Parraga
    Funding entity: MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union NextGenerationEU/PRTR”
    Budget: 085 €
    Period: 01/12/2022 – 30/11/2024

  • SCARLET A comprehensive Computer-Aided diagnosis (CAD) system based on RadiOlogic digitaL image biomarkers for prognosis of breast cancer relapse
    Principal Investigator: Carlos López Pablo (IISPV)
    Reference: TED2021-130081B-C22
    Participating GIOTEC members: Josep Gumà Padró, Kepa Amillano Parraga
    Funding entity: MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union NextGenerationEU/PRTR”
    Budget: 785 €
    Period: 30/11/2022 – 29/11/2024

  • MetLung Metabolomic profiles in blood and urine as predictors of response to immunotherapy in lung cancer patients
    Principal Investigator: Christopher Papandreou (IISPV)
    Reference: PI20/01094
    Funding entity: ISCIII, Instituto de Salud Carlos III
    Budget: 070 €
    Period: 2021 – 2023

  • TensorChrom Signal and data processing workflow for 2D chromatography based on multi-way algorithms: Application to urine metabolomics data for colorectal cancer
    Principal Investigator: Jesús Brezmes Llecha
    Reference: RTI2018-098577-B-C21
    Funding entity: MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union NextGenerationEU/PRTR”
    Budget: 275 €
    Period: 01/01/2019 – 31/08/2022

  • RadioCancers Robust radiomic features with clinical data modelling for characterizing common cancers aggressiveness and prognosis through computer analysis of multimodal radiological image
    Principal Investigator: Domènec Savi Puig Valls
    Reference: PID2019‐105789RB‐I00
    Funding entity: MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union NextGenerationEU/PRTR”
    Budget: 611 €
    Period: 2020 – 2022

  • LLAVOR Colorectal cancer markers for the selection and optimization of appropriate treatments
    Principal Investigator: Xavier Correig (URV), co-PI: Raquel Cumeras (URV)
    Reference: 2018 LLAV 00072
    Participating GIOTEC members: Josep Gumà
    Funding body: AGAUR, Agència de Gestió d’Ajuts Universitaris i de Recerca
    Budget: 20.000 €
    Period: 10/10/2020-09/04/2020

  • Modelo predictivo de supervivencia poblacional del cáncer de mama según el estadio, el subtipo molecular en el momento del diagnóstico y la adherencia al tratamiento
    Principal Investigator: Ramon Clèries Soler (IDIBELL)
    Reference: PI18/01836
    Participating GIOTEC members: Alberto Ameijide Sánchez, Marià Carulla Areste
    Funding entity: ISCIII, Instituto de Salud Carlos III
    Budget:560 €
    Period: 2019 – 2021

  • Estimación del riesgo individual de cáncer de mama según factores de riesgo conocidos de la mujer para la personalización del cribado mamográfico poblacional
    Principal Investigator: Marta Román Expósito (IMIM)
    Reference: PI17/00047
    Participating GIOTEC members: Francina Saladié Roiget
    Funding entity: ISCIII, nstituto de Salud Carlos III
    Budget:760 €
    Period: 2018 – 2020

    Clinical practice guidelines

  • Gumà J, et al., SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma. Clin Transl Oncol. 2023; In Press.

  • Aldea A, Arriola E, Borràs JM, Bosch J, Carreras MJ, Conde D, Córdoba JF, Felip E, Fontanals S, Guarga L, Majem M, Mangues I, Martínez J, Moreno E, Nadal E, Peralta S, Rodríguez MC, Serrano G, Vilà L, Viñolas N. Coordination: Gasol M, Gay D, Guarga L, Martínez J, Puig G, Sancho A. Management: Pontes C, Vallano A. Programa d’harmonització farmacoterapèutica. Pautes per a l’harmonització del tractament farmacològic del càncer de pulmó no microcític metastàtic. Versió 2.0. Barcelona: Servei Català de la Salut. Departament de Salut. Generalitat de Catalunya; 2022.

  • Aparicio J, Terrasa J, Durán I, Germà-Lluch JR, Gironés R, González-Billalabeitia E, Gumà J, Maroto P, Pinto A, García-Del-Muro X. SEOM clinical guidelines for the management of germ cell testicular cancer (2016). Clin Transl Oncol. 2016 Dec;18(12):1187-1196. DOI: 10.1007/s12094-016-1566-1 . Epub 2016 Nov 4. PMID: 27815687; PMCID: PMC5138244.

  • Rueda Domínguez A, Alfaro Lizaso J, de la Cruz Merino L, Gumá i Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Provencio Pulla M. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Clin Transl Oncol. 2015 Dec;17(12):1005-13. DOI: 10.1007/s12094-015-1429-1 . Epub 2015 Oct 26. PMID: 26497354; PMCID: PMC4689754.

  • Provencio Pulla M, Alfaro Lizaso J, de la Cruz Merino L, Gumá i Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Rueda Domínguez A. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma. Clin Transl Oncol. 2015 Dec;17(12):1014-9. DOI: 10.1007/s12094-015-1437-1 . Epub 2015 Nov 19. PMID: 26586117; PMCID: PMC4689757.

  • The Tarragona Cancer Registry is a member of the Spanish Network of Cancer Registries (REDECAN).Likewise, several members of the Tarragona Cancer Registry carried out tasks in various lines of work of this network.Since 2017, Dr.Jaume Galceran is the president of this network.

  • The Tarragona Cancer Registry is a member of the European Network of Cancer Registries (ENCR-) and the International Association of Cancer Registries (IACR-).

  • Jaume Galceran is a member of the Steering Committee of the Groupe pour l’Epidémiologie et l’Enregistrement du Cancer dans les Pays de Langue Latine (GRELL).

  • Raquel Cumeras co-leads a working group of the Metabolomics Quality Assurance and Quality Control Consortium (mQACC)

  • Participation of group members in oncological cooperative groups:

    • GECP: Grupo Español de Investigación en Cáncer de Pulmón.
    • Grupo GEICAM de Investigación en Cáncer de Mama.
    • GEICO: Grupo Español de Investigación en Cáncer de Ovario.
    • GEINO: Grupo Español de Investigación en Neurooncología.
    • GEIS: Grupo Español de Investigación en Sarcomas.
    • GEM: Grupo Español Multidisciplinar de Melanoma.
    • GEMCAD: Grupo Español Multidisciplinar en Cáncer Digestivo.
    • GETICA: Grupo Español de Terapias Inmuno-Bioloógicas en Cáncer.
    • GETNE: Grupo Español de Tumores Neuroendocrinos y Endocrinos.
    • GG: Grupo Germinal Oncológico.
    • GOTEL: Grupo Oncológico para el Tratamiento de las Enfermedades Linfoides.
    • SOGUG: Grupo Español de Oncología Genitourinaria.
    • SOLTI
    • TTCC: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello.
    • TTD: Grupo Español de Tratamiento de los Tumores Digestivos
  • Participation in innovation networks:

  • Participation of group members in other consortia:

    Treatment of COVID-19 pneumonia with low-dose radiotherapy plus standard of care versus standard of care alone in frail patients : The SEOR-GICOR IPACOVID comparative cohort trial.

    Arenas M, Piqué B, Torres-Royo L, Acosta JC, Rodríguez-Tomàs E, De Febrer G, Vasco C, Araguas P, Gómez JA, Malave B, Árquez M, Algara M, Montero A, Montero M, Simó JM, Gabaldó X, Parada D, Riu F, Sabater S, Camps J, Joven J.
    Strahlenther Onkol. 2023 Mar 31:1–10.
    DOI: 10.1007/s00066-023-02067-9
    PMID: 37000224; PMCID: PMC10064634.

    Retrospective Analysis of Vaccination Status and Predominant Viral Variants in Patients Hospitalized with COVID-19 in Reus, Spain.

    Iftimie S, López-Azcona AF, Lozano-Olmo MJ, Naval-Ferrando À, Domingo-Cortés V, Castañé H, Jiménez-Franco A, Hernández-Aguilera A, Guilarte C, Riu F, Camps J, Joven J, Castro A.
    2023 Mar 30;15(4):886.
    DOI: 10.3390/v15040886
    PMID: 37112865; PMCID: PMC10143314.

    Blood Liquid Biopsy in an Advanced Medullary Thyroid Carcinoma: A Case Study with Rearranged during Transfection Heterogeneity.

    Gumà J, Peña KB, Riu F, Lucia-Gozálvez C, Vidaller A, Maldonado V, Parada D.
    Pathobiology. 2023 Feb 2:1-7.
    DOI: 10.1159/000527184
    PMID: 36731433.

    SARS-CoV-2 Serum Viral Load and Prognostic Markers Proposal for COVID-19 Pneumonia in Low-Dose Radiation Therapy Treated Patients.

    Piqué B, Peña K, Riu F, Acosta JC, Torres-Royo L, Malave B, Araguas P, Benavides R, de Febrer G, Camps J, Joven J, Arenas M, Parada D.
    J Clin Med. 2023 Jan 19;12(3):798.
    DOI: 10.3390/jcm12030798
    PMID: 36769445; PMCID: PMC9918037.

    Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.

    Tibau A, Martínez MT, Ramos M, De La Cruz-Merino L, Santaballa A, O’Connor M, Martínez-Jañez N, Moreno F, Fernández I, Virizuela JA, Alarcón J, de La Haba-Rodríguez J, Sánchez-Rovira P, Albacar CR, Bueno Muiño C, Kelly C, Casas M, Bezares S, Rosell L, Albanell J.
    Ther Adv Med Oncol. 2023 Jan 19;15:17588359221148921.
    DOI: 10.1177/17588359221148921
    PMID: 36743520; PMCID: PMC9893357.

    Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response.

    Lejeune M, Reverté L, Sauras E, Gallardo N, Bosch R, Roso A, Petit A, Peg V, Riu F, García-Fontgivell J, Ibáñez J, Relea F, Vieites B, Bor C, de la Cruz-Merino L, Arenas M, Rodriguez V, Galera J, Korzynska A, Belhomme P, Plancoulaine B, Álvaro T, López C.
    Cancers (Basel). 2023 Jan 18;15(3):597.
    DOI: 10.3390/cancers15030597
    PMID: 36765559; PMCID: PMC9913578.

    Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.

    Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-De Dueñas E, Carañana V, Amillano K, Mina L, Malfettone A, Cortés J, Llombart-Cussac A.
    2023 Jan 18;28(1):23-32.
    DOI: 10.1093/oncolo/oyac205
    PMID: 36239405; PMCID: PMC9847524.

    Increased Hepatic ATG7 mRNA and ATG7 Protein Expression in Nonalcoholic Steatohepatitis Associated with Obesity.

    Barrientos-Riosalido A, Real M, Bertran L, Aguilar C, Martínez S, Parada D, Vives M, Sabench F, Riesco D, Castillo DD, Richart C, Auguet T.
    Int J Mol Sci. 2023 Jan 10;24(2):1324.
    DOI: 10.3390/ijms24021324
    PMID: 36674839; PMCID: PMC9867349.

    Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain

    Clèries R, Ameijide A, Buxó M, Vilardell M, Martínez JM, Font R, Marcos-Gragera R, Puigdemont M, Viñas G, Carulla M, Espinàs JA, Galceran J, Izquierdo Á, Borràs JM.
    Int J Environ Res Public Health. 2022 Dec 27;20(1):405.
    DOI: 10.3390/ijerph20010405
    PMID: 36612726; PMCID: PMC9819018.

    Immunohistochemical Algorithm for the Classification of Muscle-Invasive Urinary Bladder Carcinoma with Lymph Node Metastasis: An Institutional Study

    Peña KB, Riu F, Gumà J, Martínez-Madueño F, Miranda MJ, Vidal A, Grifoll M, Badia J, Rodriguez-Balada M, Parada D.
    J Clin Med. 2022 Dec 15;11(24):7430.
    DOI: 10.3390/jcm11247430
    PMID: 36556046; PMCID: PMC9788404.

    The untargeted urine volatilome for biomedical applications: methodology and volatilome database

    Llambrich M, Brezmes J, Cumeras R.
    Biol Proced Online. 2022 Dec 1;24(1):20.
    DOI: 10.1186/s12575-022-00184-w
    PMID: 36456991; PMCID: PMC9714113.

    Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

    Gumà J, Peña K, Riu F, Guilarte C, Hernandez A, Lucía C, Martínez-Madueño F, Miranda MJ, Cabezas I, Grifoll M, Peralta S, Serrano S, Muñoz F, Delamo L, Roig B, Borràs J, Badia J, Rodriguez-Balada M, Parada D.
    Cancers (Basel). 2022 Nov 28;14(23):5859.
    DOI: 10.3390/cancers14235859
    PMID: 36497340; PMCID: PMC9739663.

    Incidence and survival of lymphoid neoplasms in Spain, 2002-2013: A population-based study from the Spanish Network of Cancer Registries (REDECAN)

    Pla C, Solans M, Ameijide A, Sanvisens A, Carulla M, Rojas MD, Alemán MA, Sáez-Lloret I, Díaz-Del-Campo C, Marcos-Navarro AI, Sainz-de-Aja L, Aizpurua-Atxega A, Lopez-de-Munain A, Sánchez MJ, Perucha J, Franch P, Chirlaque MD, Guevara M, Galceran J, Merino S, Marcos-Gragera R; REDECAN working group.
    Front Oncol. 2022 Nov 24;12:1046307.
    DOI: 10.3389/fonc.2022.1046307
    PMID: 36508554; PMCID: PMC9731832.

    The 2022 ENCR Recommendations on recording and reporting of urothelial tumours of the urinary tract

    Galceran J, Parada D, Eden M, Tumino R, Warren AY, Martos C, Neamtiu L, Visser O, Daubisse-Marliac L.
    Front Oncol. 2022 Nov 23;12:1046239.
    DOI: 10.3389/fonc.2022.1046239
    PMID: 36505871; PMCID: PMC9727225.

    SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Gavilá J, López-González A, Cejalvo JM, Izarzugaza Y, Amillano K, Corbacho JG, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesía R, Cervantes A, Tabernero J.
    Future Oncol. 2022 Oct 6.
    DOI: 10.2217/fon-2022-0660
    PMID: 36200668.

    Patients with initial nodal involvement due to breast cancer who have received neoadjuvant chemotherapy: Combined sentinel node-radioguided surgery of the pathological node

    Fuertes Manuel J, Kohan S, Jordà Solé M, Mateu Hidalgo I, Miralles Curto M, Aguiló Sagristà O, Aguilar Alomá E, Peña González K, Lafuerza Torres A, Melé Olivé M, Repkova J, Montero Jaime MJ, Gumà Padró J.
    Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 Sep-Oct;41(5):284-291.
    DOI: 10.1016/j.remnie.2022.05.002
    PMID: 35597764.

    Breast cancer detection by analyzing the volatile organic compound (VOC) signature in human urine

    Giró Benet J, Seo M, Khine M, Gumà Padró J, Pardo Martnez A, Kurdahi F.
    Sci Rep. 2022 Sep 1;12(1):14873.
    DOI: 10.1038/s41598-022-17795-8
    PMID: 36050339; PMCID: PMC9435419.

    Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

    Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, García-Domínguez DJ, Hontecillas-Prieto L, Espejo-García P, Fernández-Román I, Provencio-Pulla M, Sánchez-Beato M, Navarro M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Sánchez-Margalet V, Rueda-Domínguez A, de la Cruz-Merino L. Clin Cancer Res. 2022 Sep 1;28(17):3658-3668.
    DOI: 10.1158/1078-0432.CCR-22-0588
    PMID: 35727601; PMCID: PMC9433956.

    Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

    Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M, Huang-Bartelett C, Lechuga Frean MJ, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, von Minckwitz G.
    J Clin Oncol. 2021 May 10;39(14):1518-1530.
    DOI: 10.1200/JCO.20.03639
    PMID: 33793299.

    Urine NMR Metabolomics for Precision Oncology in Colorectal Cancer

    Brezmes J, Llambrich M, Cumeras R, Gumà J.
    Int J Mol Sci. 2022 Sep 22;23(19):11171.
    DOI: 10.3390/ijms231911171
    PMID: 36232473; PMCID: PMC9569997.

    Proportion and stage distribution of screen-detected and non-screen-detected colorectal cancer in nine European countries: an international, population-based study

    Cardoso R, Guo F, Heisser T, De Schutter H, Van Damme N, Nilbert MC, Tybjerg AJ, Bouvier AM, Bouvier V, Launoy G, Woronoff AS, Cariou M, Robaszkiewicz M, Delafosse P, Poncet F, Walsh PM, Senore C, Rosso S, Lemmens VEPP, Elferink MAG, Tomšič S, Žagar T, Lopez de Munain Marques A, Marcos-Gragera R, Puigdemont M, Galceran J, Carulla M, Sánchez-Gil A, Chirlaque MD, Hoffmeister M, Brenner H.
    Lancet Gastroenterol Hepatol. 2022 Aug;7(8):711-723.
    DOI: 10.1016/S2468-1253(22)00084-X
    PMID: 35561739.

    Immunocytochemical Assessment of ACE2 and TMPRSS2 in Nasopharyngeal Swabs from SARS-CoV-2 Patients

    Peña KB, Gumà J, Guilarte C, Delamo L, Grifol M, Pique B, Hernandez A, Casteñé H, Riu F, Parada D.
    Front Biosci (Landmark Ed). 2022 Jul 11;27(7):217.
    DOI: 10.31083/j.fbl2707217
    PMID: 35866407.

    Overall and stage-specific survival of patients with screen-detected colorectal cancer in European countries: A population-based study in 9 countries

    Cardoso R, Guo F, Heisser T, De Schutter H, Van Damme N, Nilbert MC, Christensen J, Bouvier AM, Bouvier V, Launoy G, Woronoff AS, Cariou M, Robaszkiewicz M, Delafosse P, Poncet F, Walsh PM, Senore C, Rosso S, Lemmens VEPP, Elferink MAG, Tomšič S, Žagar T, Marques ALM, Marcos-Gragera R, Puigdemont M, Galceran J, Carulla M, Sánchez-Gil A, Chirlaque MD, Hoffmeister M, Brenner H.
    Lancet Reg Health Eur. 2022 Jul 6;21:100458.
    DOI: 10.1016/j.lanepe.2022.100458
    PMID: 35832063; PMCID: PMC9272368.

    Usefulness of the Urine Methylation Test (Bladder EpiCheck®) in Follow-Up Patients with Non-Muscle Invasive Bladder Cancer and Cytological Diagnosis of Atypical Urothelial Cells-An Institutional Study

    Peña KB, Riu F, Hernandez A, Guilarte C, Badia J, Parada D.
    J Clin Med. 2022 Jul 3;11(13):3855.
    DOI: 10.3390/jcm11133855
    PMID: 35807141; PMCID: PMC9267544.

    Neuroblastoma in Spain: Linking the national clinical database and epidemiological registries - A study by the Joint Action on Rare Cancers

    Cañete A, Peris-Bonet R, Capocaccia R, Pardo-Romaguera E, Segura V, Muñoz-López A, Fernández-Teijeiro A, Galceran-Padros J, Gatta G; Spanish Neuroblastoma Linkage Working Group (SpNbLinkWG).
    Cancer Epidemiol. 2022 Jun;78:102145.
    DOI: 10.1016/j.canep.2022.102145
    PMID: 35344745.

    Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred

    Font R, Buxó M, Ameijide A, Martínez JM, Marcos-Gragera R, Carulla M, Puigdemont M, Vilardell M, Civit S, Viñas G, Espinàs JA, Galceran J, Izquierdo Á, Borràs JM, Clèries R.
    Sci Rep. 2022 May 16;12(1):8097.
    DOI: 10.1038/s41598-022-12228-y
    PMID: 35577853; PMCID: PMC9110408.

    Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN)

    Guevara M, Molinuevo A, Salmerón D, Marcos-Gragera R, Carulla M, Chirlaque MD, Rodríguez Camblor M, Alemán A, Rojas D, Vizcaíno Batllés A, Chico M, Jiménez Chillarón R, López de Munain A, de Castro V, Sánchez MJ, Ramalle-Gómara E, Franch P, Galceran J, Ardanaz E.
    Cancers (Basel). 2022 May 15;14(10):2441.
    DOI: 10.3390/cancers14102441
    PMID: 35626046; PMCID: PMC9139549.

    Estimates of the incidence of hematological neoplasms in Spain, 2021: Study of the Spanish Network of Cancer Registries (REDECAN)

    Sanvisens A, Ameijide A, Carulla M, Marcos-Gragera R; en representación de la Red Española de Registros de Cáncer (REDECAN).
    Med Clin (Barc). 2022 Mar 25;158(6):284-290.
    DOI: 10.1016/j.medcli.2021.09.035
    PMID: 34949449.

    No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach

    Clèries R, Buxó M, Vilardell M, Ameijide A, Martínez JM, Font R, Marcos-Gragera R, Puigdemont M, Viñas G, Carulla M, Espinàs JA, Galceran J, Izquierdo Á, Borràs JM.
    Int J Environ Res Public Health. 2022 Mar 18;19(6):3605.
    DOI: 10.3390/ijerph19063605
    PMID: 35329292; PMCID: PMC8950380.

    A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE

    Payne H, Robinson A, Rappe B, Hilman S, De Giorgi U, Joniau S, Bordonaro R, Mallick S, Dourthe LM, Flores MM, Gumà J, Baron B, Duran A, Pranzo A, Serikoff A, Mott D, Herdman M, Pavesi M, De Santis M. A
    Int J Cancer. 2022 Mar 1;150(5):837-846.
    DOI: 10.1002/ijc.33845
    PMID: 34648657; PMCID: PMC9298797.

    Registration of Urothelial Tumours in Cancer Registries: How to Improve and Make It More Useful?

    Daubisse-Marliac L, Grosclaude P, Carulla M, Parada D, Vilardell L, Ameijide A, Marcos-Gragera R, Galceran J.
    Int J Environ Res Public Health. 2022 Feb 25;19(5):2714.
    DOI: 10.3390/ijerph19052714
    PMID: 35270406; PMCID: PMC8910388.

    Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography

    Román M, Louro J, Posso M, Vidal C, Bargalló X, Vázquez I, Quintana MJ, Alcántara R, Saladié F, Del Riego J, Peñalva L, Sala M, Castells X, On Behalf Of The Bele And Iris Study Groups.
    Int J Environ Res Public Health. 2022 Feb 24;19(5):2625.
    DOI: 10.3390/ijerph19052625
    PMID: 35270331; PMCID: PMC8909630.

    Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening

    Posso M, Alcántara R, Vázquez I, Comerma L, Baré M, Louro J, Quintana MJ, Román M, Marcos-Gragera R, Vernet-Tomas M, Saladie F, Vidal C, Bargalló X, Peñalva L, Sala M, Castells X; BELE study group.
    Eur Radiol. 2022 Jan;32(1):621-629.
    DOI: 10.1007/s00330-021-08118-y
    PMID: 34156554.

    Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Age-Period-Cohort Modelling

    Peremiquel-Trillas P, Frias-Gomez J, Alemany L, Ameijide A, Vilardell M, Marcos-Gragera R, Paytubi S, Ponce J, Martínez JM, Pineda M, Brunet J, Matías-Guiu X, Carulla M, Galceran J, Izquierdo Á, Borràs JM, Costas L, Clèries R.
    Int J Environ Res Public Health. 2022 Jan 27;19(3):1404.
    DOI: 10.3390/ijerph19031404
    PMID: 35162436; PMCID: PMC8834772.

    Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL; PALLAS groups and investigators.
    J Clin Oncol. 2022 Jan 20;40(3):282-293.
    DOI: 10.1200/JCO.21.02554
    PMID: 34874182.

    Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries

    Solans M, Sanvisens A, Ameijide A, Merino S, Rojas D, Alemán A, Banqueri E, Chico M, Marcos AI, de Castro V, Gil L, de Munain AL, Puigdemont M, Sánchez MJ, Perucha J, Ruiz-Armengol P, Chirlaque MD, Guevara M, Carulla M, Marcos-Gragera R.
    Sci Rep. 2022 Jan 10;12(1):323.
    DOI: 10.1038/s41598-021-03734-6
    PMID: 35013373; PMCID: PMC8748501.

    Amanida: an R package for meta-analysis of metabolomics non-integral data

    Llambrich M, Correig E, Gumà J, Brezmes J, Cumeras R.
    Bioinformatics. 2022 Jan 3;38(2):583-585.
    DOI: 10.1093/bioinformatics/btab591
    PMID: 34406360; PMCID: PMC8722753.

    Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain)

    Guarga L, Ameijide A, Marcos-Gragera R, Carulla M, Delgadillo J, Borràs JM, Galceran J.
    Sci Rep. 2021 Dec 2;11(1):23274.
    DOI: 10.1038/s41598-021-02582-8
    PMID: 34857781; PMCID: PMC8639747.

    Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.

    Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators.
    JAMA Oncol. 2021 Dec 1;7(12):1791-1799.
    DOI: 10.1001/jamaoncol.2021.4301
    Erratum in: JAMA Oncol. 2021 Nov 1;7(11):1729.
    PMID: 34617955; PMCID: PMC8498933.

    Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    Pascual T, Oliveira M, Villagrasa P, Ortega V, Paré L, Bermejo B, Morales S, Amillano K, López R, Galván P, Canes J, Salvador F, Nuciforo P, Rubio IT, Llombart-Cussac A, Di Cosimo S, Baselga J, Harbeck N, Prat A, Cortés J.
    NPJ Breast Cancer. 2021 Nov 25;7(1):145.
    DOI: 10.1038/s41523-021-00351-4
    PMID: 34824288; PMCID: PMC8616926.

    MCF-7 Drug Resistant Cell Lines Switch Their Lipid Metabolism to Triple Negative Breast Cancer Signature

    Adriá-Cebrián J, Guaita-Esteruelas S, Lam EW, Rodríguez-Balada M, Capellades J, Girona J, Jimenez-Santamaria AM, Yanes O, Masana L, Gumà J.
    Cancers (Basel). 2021 Nov 23;13(23):5871.
    DOI: 10.3390/cancers13235871
    PMID: 34884983; PMCID: PMC8657222.

    Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group

    Núñez-García B, Rodríguez-Pertierra M, Sequero S, Carvajal LG, Ruano-Ravina A, Aguiar D, Gumá J, Blanco CQ, García Arroyo FR, Garitaonaindia Y, Provencio Z, Calvo V, González-San Segundo C, Provencio M.
    Hematol Oncol. 2021 Oct;39(4):506-512.
    DOI: 10.1002/hon.2835
    PMID: 33528063.

    Prostate Cancer Survival by Risk and Other Prognostic Factors in Mallorca, Spain

    Montaño JJ, Barceló A, Franch P, Galceran J, Ameijide A, Pons J, Ramos M.
    Int J Environ Res Public Health. 2021 Oct 24;18(21):11156.
    DOI: 10.3390/ijerph182111156
    PMID: 34769675; PMCID: PMC8583124.

    Variation of Cancer Incidence between and within GRELL Countries

    Contiero P, Tagliabue G, Gatta G, Galceran J, Bulliard JL, Bertoldi M, Scaburri A, Crocetti E, On Behalf Of The Grell Geographic Analysis Working Group.
    Int J Environ Res Public Health. 2021 Sep 2;18(17):9262.
    DOI: 10.3390/ijerph18179262
    PMID: 34501852; PMCID: PMC8431723.

    Correction to: Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival

    Ripoll J, Ramos M, Montaño J, Pons J, Ameijide A, Franch P.
    BMC Cancer. 2021 Aug 26;21(1):956.
    DOI: 10.1186/s12885-021-08694-8
    Erratum for: BMC Cancer. 2021 Jun 7;21(1):676.
    PMID: 34445985; PMCID: PMC8390266.

    Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients

    Gumà J, Adriá-Cebrián J, Ruiz-Aguado B, Albacar C, Girona J, Rodríguez-Calvo R, Martínez-Micaelo N, Lam EWF, Masana L, Guaita-Esteruelas S.
    Cancers (Basel). 2021 Aug 25;13(17):4281.
    DOI: 10.3390/cancers13174281
    PMID: 34503091; PMCID: PMC8428341.

    Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study

    Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H, Van Damme N, Valerianova Z, Atanasov T, Májek O, Mužík J, Nilbert MC, Tybjerg AJ, Innos K, Mägi M, Malila N, Bouvier AM, Bouvier V, Launoy G, Woronoff AS, Cariou M, Robaszkiewicz M, Delafosse P, Poncet F, Katalinic A, Walsh PM, Senore C, Rosso S, Vincerževskienė I, Lemmens VEPP, Elferink MAG, Johannesen TB, Kørner H, Pfeffer F, Bento MJ, Rodrigues J, Alves da Costa F, Miranda A, Zadnik V, Žagar T, Lopez de Munain Marques A, Marcos-Gragera R, Puigdemont M, Galceran J, Carulla M, Chirlaque MD, Ballesta M, Sundquist K, Sundquist J, Weber M, Jordan A, Herrmann C, Mousavi M, Ryzhov A, Hoffmeister M, Brenner H.
    Lancet Oncol. 2021 Jul;22(7):1002-1013.
    DOI: 10.1016/S1470-2045(21)00199-6
    PMID: 34048685.

    Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

    Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A;
    Lancet Oncol. 2021 Jun;22(6):858-871.
    DOI: 10.1016/S1470-2045(21)00122-4
    PMID: 34019819.

    Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial

    Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A, Nogales-Fernandez E, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Rueda Dominguez A, Casanova-Espinosa M, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Labrador J, Salar-Silvestre A, Rodriguez-Abreu D, Galvez-Carvajal L, Provencio M, Sánchez-Beato M, Guirado-Risueño M, Espejo-García P, Lejeune M, Álvaro T, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA).

    J Immunother Cancer. 2021 Jun;9(6):e002323.
    DOI: 10.1136/jitc-2020-002323
    PMID: 34158317; PMCID: PMC8728348.

    Study of the Plasma and Buffy Coat in Patients with SARS-CoV-2 Infection-A Preliminary Report

    Peña KB, Riu F, Gumà J, Guilarte C, Pique B, Hernandez A, Àvila A, Parra S, Castro A, Rovira C, Cueto P, Vallverdu I, Parada D.
    Pathogens. 2021 Jun 25;10(7):805.
    DOI: 10.3390/pathogens10070805
    PMID: 34201967; PMCID: PMC8308615.

    Skin melanoma deaths within 1 or 3 years from diagnosis in Europe

    Sacchetto L, Rosso S, Comber H, Bouchardy C, Broganelli P, Galceran J, Hackl M, Katalinic A, Louwman M, Robsahm TE, Tryggvadottir L, Tumino R, Van Eycken E, Walsh PM, Zadnik V, Zanetti R.
    Int J Cancer. 2021 Jun 15;148(12):2898-2905.
    DOI: 10.1002/ijc.33479
    PMID: 33497469.

    Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival

    Ripoll J, Ramos M, Montaño J, Pons J, Ameijide A, Franch P.
    BMC Cancer. 2021 Jun 7;21(1):676.
    DOI: 10.1186/s12885-021-08418-y
    Erratum in: BMC Cancer. 2021 Aug 26;21(1):956.
    PMID: 34098901; PMCID: PMC8186217.

    Lung, Breast and Colorectal Cancer Incidence by Socioeconomic Status in Spain: A Population-Based Multilevel Study

    Redondo-Sánchez D, Marcos-Gragera R, Carulla M, Lopez de Munain A, Sabater Gregori C, Jimenez Chillarón R, Guevara M, Nuñez O, Fernández-Navarro P, Sánchez MJ, Luque-Fernandez MA.
    Cancers (Basel). 2021 Jun 5;13(11):2820.
    DOI: 10.3390/cancers13112820
    PMID: 34198798; PMCID: PMC8201149.

    Circulating microRNAs modulating glycolysis as non-invasive prognostic biomarkers of HNSCC

    Avilés-Jurado FX, Muñoz C, Meler C, Flores JC, Gumà J, Benaiges E, Mora J, Camacho M, León X, Vilaseca I, Terra X.
    Eur Arch Otorhinolaryngol. 2021 May;278(5):1585-1594.
    DOI: 10.1007/s00405-020-06240-z
    PMID: 32737645.

    Comprehensive Volatilome and Metabolome Signatures of Colorectal Cancer in Urine: A Systematic Review and Meta-Analysis

    Mallafré-Muro C, Llambrich M, Cumeras R, Pardo A, Brezmes J, Marco S, Gumà J.
    Cancers (Basel). 2021 May 21;13(11):2534.
    DOI: 10.3390/cancers13112534
    PMID: 34064065; PMCID: PMC8196698.

    Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

    Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M, Huang-Bartelett C, Lechuga Frean MJ, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, von Minckwitz G.
    J Clin Oncol. 2021 May 10;39(14):1518-1530.
    DOI: 10.1200/JCO.20.03639
    PMID: 33793299.

    Population-based risk assessment of second primary cancers following a first head and neck cancer: patterns of association and difficulties of its analysis

    Rubió-Casadevall J, Galceran J, Ameijide A, Puigdemont M, Llauradó L, Marruecos J, Izquierdo A, Carulla M, Borràs JL, Marcos-Gragera R, Gumà J.
    Clin Transl Oncol. 2021 Apr;23(4):788-798.
    DOI: 10.1007/s12094-020-02470-z
    PMID: 32815088.

    Succinate Pathway in Head and Neck Squamous Cell Carcinoma: Potential as a Diagnostic and Prognostic Marker

    Terra X, Ceperuelo-Mallafré V, Merma C, Benaiges E, Bosch R, Castillo P, Flores JC, León X, Valduvieco I, Basté N, Cámara M, Lejeune M, Gumà J, Vendrell J, Vilaseca I, Fernández-Veledo S, Avilés-Jurado FX.
    Cancers (Basel). 2021 Apr 1;13(7):1653.
    DOI: 10.3390/cancers13071653
    PMID: 33916314; PMCID: PMC8037494.

    First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain

    Iftimie S, López-Azcona AF, Vallverdú I, Hernández-Flix S, de Febrer G, Parra S, Hernández-Aguilera A, Riu F, Joven J, Andreychuk N, Baiges-Gaya G, Ballester F, Benavent M, Burdeos J, Català A, Castañé È, Castañé H, Colom J, Feliu M, Gabaldó X, Garrido D, Garrido P, Gil J, Guelbenzu P, Lozano C, Marimon F, Pardo P, Pujol I, Rabassa A, Revuelta L, Ríos M, Rius-Gordillo N, Rodríguez-Tomàs E, Rojewski W, Roquer-Fanlo E, Sabaté N, Teixidó A, Vasco C, Camps J, Castro A.
    PLoS One. 2021 Mar 31;16(3):e0248029.
    DOI: 10.1371/journal.pone.0248029
    PMID: 33788866; PMCID: PMC8011765.

    Cancer incidence estimation from mortality data: a validation study within a population-based cancer registry

    Redondo-Sánchez D, Rodríguez-Barranco M, Ameijide A, Alonso FJ, Fernández-Navarro P, Jiménez-Moleón JJ, Sánchez MJ.
    Popul Health Metr. 2021 Mar 23;19(1):18.
    DOI: 10.1186/s12963-021-00248-1
    PMID: 33757540; PMCID: PMC7988947.

    Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening

    Louro J, Román M, Posso M, Vázquez I, Saladié F, Rodriguez-Arana A, Quintana MJ, Domingo L, Baré M, Marcos-Gragera R, Vernet-Tomas M, Sala M, Castells X; BELE and IRIS Study Groups.
    PLoS One. 2021 Mar 23;16(3):e0248930.
    DOI: 10.1371/journal.pone.0248930
    PMID: 33755692; PMCID: PMC7987139.

    Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)

    Franco F, Guirado M, Martínez-Banaclocha N, Gumà J, Lavernia J, Gómez-Codina J, Rodriguez-Abreu D, Martínez F, Barrajón E, Méndez M, Calvo V, Provencio M.
    Curr Oncol. 2021 Mar 16;28(2):1249-1255.
    DOI: 10.3390/curroncol28020118
    PMID: 33809772; PMCID: PMC8025807.

    Liquid-based cytological and immunohistochemical study of nasopharyngeal swab from persons under investigation for SARS-CoV-2 infection

    Parada D, Peña KB, Gumà J, Guilarte C, Riu F.
    Histopathology. 2021 Mar;78(4):586-592.
    DOI: 10.1111/his.14257
    PMID: 32970870; PMCID: PMC7537171.

    Predicting the rising incidence and mortality of endometrial cancers among women aged 65-74 years in Catalonia

    Frias-Gomez J, Peremiquel-Trillas P, Alemany L, Ameijide A, Marcos-Gragera R, Ponce J, Brunet J, Matias-Guiu X, Galceran J, Izquierdo Á, Borràs JM, Costas L, Clèries R.
    Maturitas. 2021 Feb;144:11-15.
    DOI: 10.1016/j.maturitas.2020.09.006
    PMID: 33358202.

    Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer

    Maroto P, García Del Muro X, Valverde C, Pinto A, Sanchez A, Guma J, Alonso T, Martínez Del Prado P, Vazquez S, Mellado B, Aparicio J, Fernandez-Aramburo A, Girones R, Terrasa J; Spanish Germ Cell Cancer Group.
    Urol Oncol. 2021 Feb;39(2):135.e17-135.e23.
    DOI: 10.1016/j.urolonc.2020.11.004
    PMID: 33189529.

    Risk of breast cancer two years after a benign biopsy depends on the mammographic feature prompting recall

    Vernet-Tomás M, Louro J, Román M, Saladié F, Posso M, Prieto M, Vázquez I, Baré M, Peñalva L, Vidal C, Bargalló X, Sánchez M, Ferrer J, A Espinàs J, Quintana MJ, Rodríguez-Arana A, Castells X; BELE study group.
    Maturitas. 2021 Feb;144:53-59.
    DOI: 10.1016/j.maturitas.2020.10.024
    PMID: 33358209.

    Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice

    Fernández-Montes A, de Velasco G, Aguín S, Farriols C, Guirado-Risueño M, Jerviz-Guía VG, Baeza-Nadal MV, Chicas-Sett R, Fírvida JL, García-Navalón F, Martín P, Perezagua-Marín C, Rodríguez D, Santamaría J, Saurí T, Cobo M.
    Curr Treat Options Oncol. 2021 Feb 26;22(3):26.
    DOI: 10.1007/s11864-021-00816-5
    PMID: 33635493.

    Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group

    Aparicio J, García Del Muro X, Maroto P, Terrasa J, Castellano D, Bastús R, Gumà J, Sagastibeltza N, Durán I, Ochenduszko S, Meana JA, García-Sánchez J, Arranz JA, Gironés R, Germà JR.
    Clin Transl Oncol. 2021 Jan;23(1):58-64.
    DOI: 10.1007/s12094-020-02393-9
    PMID: 32462393.

    Total Tumor Load of mRNA Cytokeratin 19 in the Sentinel Lymph Node as a Predictive Value of Axillary Lymphadenectomy in Patients with Neoadjuvant Breast Cancer

    Peña KB, Kepa A, Cochs A, Riu F, Parada D, Gumà J.
    Genes (Basel). 2021 Jan 8;12(1):77.
    DOI: 10.3390/genes12010077
    PMID: 33435629; PMCID: PMC7826715.

    Incidence and Clinical Pattern of Contralateral Synchronous and Metachronous Germ Cell Testicular Cancer

    Maroto P, García Del Muro X, Valverde C, Pinto A, Sanchez A, Guma J, Alonso T, Martínez Del Prado P, Vazquez S, Mellado B, Aparicio J, Fernandez-Aramburo A, Girones R, Terrasa J; Spanish Germ Cell Cancer Group.Urol Oncol. 2020 Nov 11:S1078-1439(20)30573-1. Epub ahead of print. PMID: 33189529.

    doi: 10.1016/j.urolonc.2020.11.004

    Liquid-based cytological and immunohistochemical study of nasopharyngeal swab from persons under investigation for SARS-CoV-2 infection

    Parada D D, Peña KB, Gumá J, Guilarte C, Riu F.  Histopathology. 2020 Sep 24:10.1111/his.14257. doi: 10.1111/his.14257. Epub ahead of print. PMID: 32970870; PMCID: PMC7537171.

    DOI: 10.1111/his.14257

    Population-based risk assessment of second primary cancers following a first head and neck cancer: patterns of association and difficulties of its analysis.

    Rubió-Casadevall J, Galceran J, Ameijide A, Puigdemont M, Llauradó L, Marruecos J, Izquierdo A, Carulla M, Borràs JL, Marcos-Gragera R, Gumà J.Clin Transl Oncol. 2020 Aug 19. Epub ahead of print. PMID: 32815088.

    DOI: 10.1007/s12094-020-02470-z

    Proactive and systematic multidimensional needs assessment in patients with advanced cancer approaching palliative care: a study protocol

    Pergolizzi D, Crespo I, Balaguer A, Monforte-Royo C, Alonso-Babarro A, Arantzamendi M, Belar A, Centeno C, Goni-Fuste B, Julià-Torras J, Martinez M, Mateo-Ortega D, May L, Moreno-Alonso D, Nabal Vicuña M, Noguera A, Pascual A, Perez-Bret E, Rocafort J, Rodríguez-Prat A, Rodriguez D, Sala C, Serna J, Porta-Sales J. BMJ Open. 2020 Feb 4;10(2):e034413. PMID: 32024792; PMCID: PMC7045209

    DOI: 10.1136/bmjopen-2019-034413

    A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01)

    Balana C, Vaz MA, Sepúlveda JM, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C. Neuro Oncol. 2020 Apr 24:noaa107. Epub ahead of print. PMID: 32328662.

    DOI: 10.1093/neuonc/noaa107

    Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

    Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, Escrivá-de-Romaní S, Manso L, Adamo B, Martínez E, Cortés J, Vazquez S, Perelló A, Garau I, Melé M, Martínez N, Montaño A, Bermejo B, Morales S, Echarri MJ, Vega E, González-Farré B, Martínez D, Galván P, Canes J, Nuciforo P, Gonzalez X, Prat A. Clin Cancer Res. 2020 Nov 15;26(22):5820-5829. Epub 2020 Sep 16. PMID: 32938620.

    DOI: 10.1158/1078-0432.CCR-20-0844

    Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.

    Laquente B, Macarulla T, Bugés C, Martín M, García C, Pericay C, Merino S, Visa L, Martín T, Pedraza M, Carnero B, Guardeño R, Verdaguer H, Mut A, Vilanova D, García A. BMC Palliat Care. 2020 Jul 10;19(1):103. PMID: 32650765; PMCID: PMC7350578.

    DOI: 10.1186/s12904-020-00610-4

    Circulating microRNAs modulating glycolysis as non-invasive prognostic biomarkers of HNSCC.

    Avilés-Jurado FX, Muñoz C, Meler C, Flores JC, Gumà J, Benaiges E, Mora J, Camacho M, León X, Vilaseca I, Terra X. Eur Arch Otorhinolaryngol. 2020 Jul 31. Epub ahead of print. PMID: 32737645.

    DOI: 10.1007/s00405-020-06240-z

    Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group

    Aparicio J, García Del Muro X, Maroto P, Terrasa J, Castellano D, Bastús R, Gumà J, Sagastibeltza N, Durán I, Ochenduszko S, Meana JA, García-Sánchez J, Arranz JA, Gironés R, Germà JR. Clin Transl Oncol. 2020 May 27. Epub ahead of print. PMID: 32462393.

    DOI: 10.1007/s12094-020-02393-9

    Missing data imputation and synthetic data simulation through modeling graphical probabilistic dependencies between variables (ModGraProDep): An application to breast cancer survival

    Vilardell M, Buxo M, Cleries R, Martinez JM, Garcia G, Ameijide A, Font R, Civit S, Marcos-Gragera R, Vilardell ML, Carulla M, Espinas JA, Galceran J, Izquierdo A, Borras JM.
    Artif Intell Med. 2020 Jul;107:101875.

    DOI: 10.1016/j.artmed.2020.101875

    Differences in breast cancer risk after benign breast disease by type of screening diagnosis.

    Louro J, Roman M, Posso M, Comerma L, Vidal C, Saladie F, Alcantara R, Sanchez M, Quintana MJ, del Riego J, Ferrer J, Penalva L, Bargallo X, Prieto M, Sala M, Castells X.
    Breast. 2020 Dec;54:343-348.

    DOI: 10.1016/j.breast.2020.09.005

    Rare thyroid malignancies in Europe: Data from the informationnetwork on rare cancers in Europe (RARECAREnet).

    Locati L, Cavalieri S, Dal Maso L, Busco S, Anderson L, Botta L, Bento MJ, Carulla M, Chirlaque López MD, Fusco M, Guevara M, Innos K, BørgeJohannesen T, Micallef R, Minicozzi P, Panato C, Petrova D, Rubio Casadevall J, Smailyte G, Vitale MF, Trama A.
    Oral Oncol. 2020 Sep;108:104766.

    DOI: 10.1016/j.oraloncology.2020.104766 

    A population perspective on the use of external beam radiotherapy in Catalonia, Spain.

    Corral J, Solà J, Galceran J, Marcos-Gragera R, Carulla M, Izquierdo Á, Vilardell L, Llauradó L, Espinàs J, Borras JM.
    Clin Transl Oncol. 2020 Dec;22(12):2222-2229.

    DOI: 10.1007/s12094-020-02355-1

    Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group.

    Núñez-García B, Rodríguez-Pertierra M, Sequero S, Carvajal LG, Ruano-Ravina A, Aguiar D, Gumá J, Blanco CQ, García Arroyo FR, Garitaonaindia Y, Provencio Z, Calvo V, González-San Segundo C, Provencio M.
    First published: Hematol Oncol. 2020 Dec

    DOI: 10.1002/hon.2835

    Excess mortality among breast cancer patients in early stages in Tarragona and Gerona

    Clèries R, Ameijide A, Buxó M, Vilardell M, Martínez JM, Marcos-Gragera R, Vilardell ML, Carulla M, Espinàs JA, Galceran J, Borràs JM, Izquierdo Á.
    Gac Sanit. Jul-Aug 2020;34(4):356-362.

    DOI: 10.1016/j.gaceta.2018.09.008.

    Protocolo del Estudio Poblacional Multinivel de las Desigualdades Socioeconómicas en la Distribución Geográfica de la Incidencia, la Mortalidad y la Supervivencia Neta del Cáncer en España: Estudio DESOCANES.

    Luque-Fernández MA, Redondo-Sánchez D, Fernández P, Salamanca-Fernández E, Marcos-Gragera R, Guevara M, Carulla M, Jiménez R, Núñez O, Sabater C, López de Munain A, Chirlaque MD, Mateos A, Rodríguez-Barranco M, Espín J, Pollán M, Sánchez MJ.
    2020 JuL 13 [Epub ahead of print]. Gac Sanit.

    DOI: 10.1016/j.gaceta.2020.02.015

    Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients

    Rodríguez-Balada M, Roig B, Melé M, Albacar C, Serrano S, Salvat M, Querol M, Borràs J, Martorell L, Gumà J. Clin Biochem. 2020 Feb;76:17-23. Epub 2019 Nov 28. PMID: 31786208.

    DOI: 10.1016/j.clinbiochem.2019.11.014

    Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

    Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA. J Clin Med. 2019 Dec 11;8(12):2180. PMID: 31835708; PMCID: PMC6947627.

    DOI: 10.3390/jcm8122180

    Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Cuyàs E, Fernández-Arroyo S, Buxó M, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Verdura S, Brunet J, López-Bonet E, Garcia M, Saidani S, Joven J, Martin-Castillo B, Menendez JA. Aging (Albany NY). 2019 May 9;11(9):2874-2888. PMID: 31076561; PMCID: PMC6535060.

    DOI: 10.18632/aging.101960

    The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.

    Cuyàs E, Buxó M, Ferri Iglesias MJ, Verdura S, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Joven J, Brunet J, López-Bonet E, Garcia M, Saidani S, Queralt Moles X, Martin-Castillo B, Menendez JA. Front Oncol. 2019 Mar 28;9:193. PMID: 30984619; PMCID: PMC6447648.

    DOI: 10.3389/fonc.2019.00193

    Effects of radiotherapy on plasma energy metabolites in patients with breast cancer who received neoadjuvant chemotherapy

    Arenas M, Fernández-Arroyo S, Rodríguez-Tomàs E, Sabater S, Murria Y, Gascón M, Amillano K, Melé M, Camps J, Joven J. Clin Transl Oncol. 2020 Jul;22(7):1078-1085. Epub 2019 Nov 2. PMID: 31679126.

    DOI: 10.1007/s12094-019-02232-6

    Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group

    Aparicio J, Sánchez-Muñoz A, Ochenduszko S, Gumà J, Fernández-Aramburo A, García Del Muro X, Quiroga V, Sastre J, Alonso-Gordoa T, Sagastibelza N, Maroto P, Gómez de Liaño A, Vázquez S, Diz P, Durán I, Domenech M, Pinto A, Hernández A, González-Billalabeitia E, Terrasa J. J Urol. 2019 Oct;202(4):742-747. Epub 2019 Sep 6. PMID: 31163007.

    DOI: 10.1097/JU.0000000000000366

    Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

    Méndez M, Torrente M, Sánchez-Beato M, González-Rincón J, Royuela A, Gómez-Codina J, de la Cruz-Merino L, Rueda A, Llanos M, Quero C, Rodríguez-Abreu D, Gumá J, Monsalvo S, Sabin P, Provencio M. Hematol Oncol. 2019 Apr;37(2):143-150. Epub 2019 Apr 4. PMID: 30840776.

    DOI: 10.1002/hon.2601

    Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years

    Provencio M, Franco F, Gómez-Codina J, Quero Blanco C, Llanos M, Garcia-Arroyo F, de la Cruz L, Gumá J, Delgado JR, Álvarez R, Chacón JI, Royuela A, Rueda A. Leuk Lymphoma. 2019 Mar;60(3):856-859. Epub 2018 Sep 20. PMID: 30234403.

    DOI: 10.1080/10428194.2018.1509322

Team Members

  • Group leader

    • Dr. Josep Gumà Padró
    • Dr. Joan Lluís Borràs Balada
  • Research lines heads

    • Agustina Sirgo Rodríguez
    • Marta Rodríguez Balada
    • Francesc Riu Ferrando
    • Jaume Galceran Padrós
    • Raquel Cumeras
  • Investigador/a sénior

    • Sara Fernández Castillejo
    • Bàrbara Roig Bourgine
    • Karla Peña González
    • Xavier Cardó Moreno
    • Sandra Guaita Esteruelas
    • David Parada Domínguez
  • Pre-doctoral Researcher

    • Clara Beatriz Lucia Gozálvez
  • MD

    • Sara Serrano Solares
    • Belen Ruiz Aguado
    • Beatriz Rubio Cantavella
    • Dulce Rodríguez Mesa
    • Jana Repkovà
    • Rosana Queralt Escarré
    • Sergio Peralta Muño
    • Félix Muñoz Boza
    • Vanesa Morente Laguna
    • Maria José Miranda Pallares
    • Sandra Merino Varela
    • Mireia Melé Olivé
    • Maria Masvidal Hernández
    • Francisca Martínez Madueño
    • Cristina Martí Blanco
    • Inés Cabezas Montero
    • David Ricardo Bottaro Parra
    • Kepa Amillano Parraga
    • Cinta Albacar Miró
    • Alba Cochs Sarobé
    • Lola Delamo Palomares
    • Marc Grifoll Escoda
    • Anna Vidal Rodríguez
  • Research Scientist

    • Cristina Miracle Huguet
    • Francina Saladié Roiget
    • Clàudia Pla González
    • Xavier Collado Castro
    • Marià Carulla Areste
    • Jàmnica Bigorra Román
    • Alberto Ameijide Sánchez
  • Nurses

    • Montse Sánchez Galino
    • Mònica Salvat Casas
    • M. Dolors Salsench Boronat
    • Montserrat Querol Garcia
    • Margarita Moreno Mancho
    • Sandra Mateu Riba
    • Araceli Jiménez López
    • Berta Caballé Gutiérrez
    • Cecília González Gómez-Navarro
    • Maite Parejo Arrondo
  • Technicians

    • Laia Llauradó March
    • Lydia Díaz Suárez
    • Alexandra Cabré Pedrosa
    • Anna Alimbau Sendrós
    • Joan Badia Cabré
    • Héctor Villalba Ordóñez
  • Documentalist

    • Laia Llauradó March
    • Sònia Cano Gallego
  • Administrative Technicians

    • Lydia Díaz Suárez
    • Alexandra Cabré Pedrosa
    • Mònica Barrientos Palomares